Amgen Inc Stock Price, News & Analysis

Amgen has entered a research collaboration with Generate Biomedicines to develop protein therapeutics targeting five clinical indications. Amgen will provide $50 million upfront, with potential total deal value reaching $1.9 billion. The agreement includes milestone payments of up to $370 million per program, along with royalties. This partnership aims to combine Amgen's protein engineering expertise with Generate's AI-driven drug discovery platform, significantly enhancing the efficiency of creating innovative treatments for complex diseases.

Amgen will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 1:00 p.m. ET. The presentation will be led by Robert A. Bradway, the CEO. The live audio will be available for public access via Amgen's website. This event underscores Amgen's commitment to addressing serious illnesses through innovative therapeutics. The webcast will also be archived for at least 90 days for those unable to attend live.

Amgen announced FDA approval for Otezla^® (apremilast) to treat adults with plaque psoriasis, making it the first oral treatment approved for all severity levels. The approval stems from the Phase 3 ADVANCE trial, which showed significant efficacy, with 21.6% achieving treatment success at week 16 compared to 4.1% for placebo (p<0.0001). Otezla, which has been used by over 650,000 patients globally, offers an alternative for those inadequately managed by topical therapies. Approximately 8 million Americans suffer from plaque psoriasis, indicating a substantial market opportunity for Amgen.

Amgen has announced the FDA approval of Tezspire (tezepelumab-ekko), a first-in-class biologic for severe asthma treatment in patients aged 12 and older. This landmark approval allows it to be used without phenotypic limitations, targeting inflammation directly. Tezspire outperformed placebos in the NAVIGATOR Phase 3 trial across primary and secondary endpoints. The drug aims to aid the 34 million individuals suffering from severe asthma worldwide, offering a new treatment option for those previously inadequately addressed by existing therapies.

Amgen (NASDAQ: AMGN) announced new data from its hematology pipeline to be presented at the 63rd ASH Annual Meeting from Dec. 11-14, 2021. The data emphasizes Amgen's dedication to improving patient outcomes in blood cancers. Key presentations include updated Phase 3 trial results for BLINCYTO showing improved survival rates in children with B-ALL, and promising safety and efficacy data for subcutaneous BLINCYTO in adults. Results from the Pregnancy Surveillance Program for Nplate highlighted no significant safety concerns. Important abstracts detailing real-world outcomes in multiple myeloma will also be presented.

Amgen's Board of Directors declared a $1.94 per share dividend for Q1 2022, marking a 10% increase from the previous quarters. The dividend will be paid on March 8, 2022 to shareholders of record as of February 15, 2022. This increase reflects the company's commitment to returning value to shareholders while maintaining sustainable growth strategies. Amgen continues to focus on developing innovative therapeutics and addressing unmet medical needs in healthcare.

Amgen announced positive top-line results from the Phase 3 DISCREET trial evaluating Otezla (apremilast) for adults with moderate to severe genital psoriasis. The trial achieved significant improvement in the primary endpoint at week 16, with Otezla 30 mg twice daily showing a marked reduction in modified static Physician's Global Assessment of Genitalia scores compared to placebo. Secondary endpoints, including itch severity and body surface area involvement, also saw significant improvements. The study's adverse events aligned with Otezla's safety profile, primarily involving gastrointestinal symptoms.

Amgen (AMGN) announced the FDA approval for expanding the KYPROLIS (carfilzomib) labeling to include its use in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and dexamethasone for treating relapsed or refractory multiple myeloma in adults with one to three prior therapies. The decision is based on the Phase 2 PLEIADES study, showing an impressively high overall response rate of 84.8%. This combination aims to enhance patient convenience by reducing administration time and burden. Amgen plans to submit global marketing applications soon.